PREDNISOLONE , MabThera 100 mg concentrate for solution for infusion, PREDNISONE , MabThera 500 mg concentrate for solution for infusion
P170922J
Phase 2 small_molecule active
Quick answer
PREDNISOLONE , MabThera 100 mg concentrate for solution for infusion, PREDNISONE , MabThera 500 mg concentrate for solution for infusion for Minimal Change Nephrotic Syndrom is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Minimal Change Nephrotic Syndrom
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active